News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,163 Results
Type
Article (3144)
Company Profile (4)
Press Release (15015)
Multimedia
Podcasts (10)
Webinars (2)
Section
Business (7100)
Career Advice (96)
Deals (999)
Drug Delivery (13)
Drug Development (2675)
Employer Resources (13)
FDA (594)
Job Trends (631)
News (11110)
Policy (1043)
Tag
2024 Biotech Bay Standard (1)
2024 Genetown Standard (1)
Academia (70)
Accelerated approval (1)
Allergies (6)
Alliances (1493)
ALS (2)
Alzheimer's disease (23)
Antibody-drug conjugate (ADC) (8)
Approvals (597)
Artificial intelligence (8)
Automation (1)
Bankruptcy (9)
Best Places to Work (363)
BIOSECURE Act (2)
Biosimilars (17)
Biotechnology (2)
Brain cancer (2)
Breast cancer (20)
Cancer (77)
Cardiovascular disease (16)
Career advice (74)
Career pathing (2)
CAR-T (8)
Cell therapy (18)
Cervical cancer (1)
Clinical research (2151)
Collaboration (23)
Compensation (5)
Complete response letters (1)
COVID-19 (101)
CRISPR (1)
C-suite (24)
Data (31)
Depression (2)
Diabetes (5)
Diagnostics (56)
Diversity, equity & inclusion (3)
Drug discovery (9)
Drug pricing (22)
Duchenne muscular dystrophy (2)
Earnings (1537)
Editorial (6)
Employer branding (7)
Employer resources (12)
Events (1239)
Executive appointments (67)
FDA (622)
Featured Employer (1)
Funding (22)
Gene editing (3)
Generative AI (2)
Gene therapy (25)
GLP-1 (48)
Government (189)
Guidances (3)
Healthcare (379)
Huntington's disease (3)
IgA nephropathy (8)
Immunology and inflammation (12)
Indications (1)
Infectious disease (102)
Inflammatory bowel disease (1)
Inflation Reduction Act (2)
Intellectual property (1)
Interviews (17)
IPO (286)
IRA (12)
Job creations (278)
Job search strategy (73)
Labor market (3)
Layoffs (65)
Legal (348)
Liver cancer (3)
Lung cancer (6)
Management (2)
Manufacturing (13)
Medical device (61)
Medtech (61)
Mergers & acquisitions (710)
Metabolic disorders (20)
Multiple sclerosis (4)
Neurodegenerative disease (5)
Neuropsychiatric disorders (1)
Neuroscience (38)
NextGen: Class of 2025 (243)
Non-profit (61)
Northern California (43)
Now hiring (2)
Obesity (14)
Opinion (37)
Pain (1)
Parkinson's disease (2)
Partnered (1)
Patents (12)
Patient recruitment (2)
Peanut (4)
People (3533)
Phase I (623)
Phase II (869)
Phase III (958)
Pipeline (28)
Policy (22)
Postmarket research (148)
Preclinical (189)
Prostate cancer (12)
Radiopharmaceuticals (29)
Rare diseases (13)
Real estate (174)
Recruiting (5)
Regulatory (602)
Reports (1)
Research institute (68)
Resumes & cover letters (24)
Schizophrenia (2)
Series A (10)
Series B (5)
Sickle cell disease (3)
Southern California (25)
Special edition (4)
Spinal muscular atrophy (39)
Sponsored (3)
Startups (274)
Stomach cancer (1)
Supply chain (4)
Tariffs (10)
The Weekly (10)
United States (348)
Vaccines (14)
Venture capitalists (8)
Weight loss (9)
Women's health (1)
Date
Today (7)
Last 7 days (25)
Last 30 days (65)
Last 365 days (786)
2025 (263)
2024 (840)
2023 (819)
2022 (2045)
2021 (1817)
2020 (1403)
2019 (1200)
2018 (965)
2017 (1221)
2016 (911)
2015 (985)
2014 (735)
2013 (602)
2012 (636)
2011 (611)
2010 (623)
Location
Africa (51)
Asia (1297)
Australia (183)
California (87)
Canada (38)
China (8)
Colorado (3)
Connecticut (6)
Delaware (7)
Europe (4497)
Florida (5)
Illinois (5)
Indiana (7)
Japan (1)
Kansas (1)
Maryland (5)
Massachusetts (123)
Michigan (2)
Minnesota (2)
Nebraska (1)
Nevada (1)
New Hampshire (3)
New Jersey (37)
New Mexico (1)
New York (20)
North Carolina (17)
Northern California (43)
Ohio (4)
Pennsylvania (13)
Puerto Rico (1)
South America (51)
Southern California (25)
Tennessee (1)
Texas (9)
Virginia (2)
Washington D.C. (3)
Washington State (7)
Wisconsin (1)
18,163 Results for "novartis".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome sign for the biopharma ecosystem, which has been battered by macro headwinds such as tariffs and the possibility of new drug pricing pressures.
April 30, 2025
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Drops up to $1.7B to Bolster Oligo Pipeline With Regulus Buy
At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for rare autosomal dominant polycystic kidney disease.
April 30, 2025
·
2 min read
·
Tristan Manalac
1 of 1,817
Next
